Who is Tu Youyou
Tu Youyou is a Chinese pharmaceutical researcher whose work on artemisinin received the 2015 Nobel Prize in Physiology or Medicine.[2] She was born in Ningbo on 30 December 1930.[6] Her career developed around natural substances and their development into medicines for malaria.[2]
Education and early laboratory work
She studied pharmacy from 1951 to 1955 at the institution that became Beijing Medical College. Training included medicinal plant identification, extraction and chemical structure determination. Combining botany with chemistry provided tools for investigating compounds whose presence in plants required experimental confirmation.[6]
In Nature Medicine she recalled joining the Academy of Traditional Chinese Medicine after graduating in 1955. Between 1959 and 1962 she completed a two-and-a-half-year course in Chinese medicine for people with biomedical training. Her subsequent research combined this education with the methods learned in pharmacy.[8]
Her first publication, coauthored with Lou Zhicen in 1958, examined Lobelia chinensis, traditionally used against schistosomiasis. It was a pharmacognostic study of the plant.[1]
Project 523
Project 523 began in 1967 to investigate antimalarial treatments. Tu took charge of her institute’s group in 1969. Su and Miller’s reconstruction examines meeting records and presentations from this programme, involving numerous teams, and places her contribution within a coordinated national research effort.[7]
From Artemisia annua to artemisinin
Ge Hong’s account of qinghao led Tu to reconsider extraction temperature. Her team used a low-temperature procedure and separated an acidic fraction from a neutral fraction with antimalarial activity. The advance combined historical reading, procedural changes and experimental work on extracts.[9]
In 1972 the team isolated an active crystalline substance, named qinghaosu or artemisinin. Determining its structure required collaboration with other institutes; structural results appeared under collective authorship in 1977. The compound is a sesquiterpene lactone, chemically different from the antimalarials then known.[10]
Trials, derivatives and publications
Tu’s Nobel lecture timeline distinguishes the 1972 neutral-extract trial from artemisinin testing in 1973. It dates the finding of dihydroartemisinin to September 1973. New-drug approvals followed later: artemisinin in 1986 and dihydroartemisinin in 1992.[11]
Studies on the constituents of Artemisia annua L. II appeared in Planta Medica in 1982. Its authors include Tu, Ni, Zhong, Li, Cui, Zhang, Wang, Ji and Liang. The paper forms part of the scientific record of the plant’s constituents and identifies her collaborators.[12]
Medicines and malaria control
Artemisinin-based combination therapies pair a derivative of the compound with another medicine. WHO explains that these components perform complementary roles against the parasite. Partial resistance appears as slower parasite clearance, making continued monitoring of treatment efficacy necessary.[13]
Tu’s research led to defined and evaluated medicines. WHO does not support using Artemisia plant material to prevent or treat malaria because variable composition and preparation cannot ensure dosage, quality or clinical efficacy. This distinction explains the transition from a botanical lead to a pharmaceutical product.[14]
Institutional work and reference book
The 2015 Warren Alpert Foundation symposium introduced her as professor and director of the Qinghaosu Research Center at the Institute of Chinese Materia Medica. Her career involved research and chemistry leadership roles within the same academic structure, later renamed the China Academy of Chinese Medical Sciences.[19]
In 2017 she published From Artemisia annua L. to Artemisinins, with contributions from team members. Its sections address the plant, artemisinin, dihydroartemisinin and other derivatives, tracing the path from botanical origins to the chemical and pharmacological development of this antimalarial drug family.[15]
Nobel Prize and other recognition
She received the Lasker–DeBakey Clinical Medical Research Award in 2011.[9] In 2015 she shared the Warren Alpert Prize with Ruth S. Nussenzweig and Victor Nussenzweig, recognising contributions to chemistry, parasitology, and pharmaceutical and vaccine approaches to malaria.[16]
She received half of the 2015 Nobel Prize for her malaria work; William C. Campbell and Satoshi Ōmura shared the other half.[2] China awarded her its highest state science and technology prize for 2016. Ministry records also note recognition of the team in 1978 and the new drug in 1979.[17]
The official decision of 17 September 2019 named Tu among the recipients of the Medal of the Republic. It added to national and international recognition of her pharmaceutical research.[18]
Archive and international recognition
The Nobel Museum displays a report documenting her research from 1971 to 1978. Her scientific career developed without a doctorate or training abroad. In 1981 she presented the findings at an international meeting associated with WHO, the World Bank and the United Nations, helping disseminate the work conducted in China.[20]
Solvents and working conditions in research
During extract preparation, Tu Youyou described prolonged solvent exposure and inadequate equipment and ventilation, alongside health problems among team members.[1]
The episode provides a specific industrial-hygiene case: what happens when an extraction process is scaled up without adapting working conditions?
A preventive reading can compare solvent transfer, extraction and recovery tasks, asking where vapours are released, who works nearby and how exposure is controlled. These are questions for analysing a process, not instructions for reproducing it.
HSE guidance on solvents confirms the relevance of the amount used, the method of application and available ventilation.[5]
Analysing these conditions helps identify the exposure controls needed at each process stage and assess whether they remain suitable as work is scaled up.
